Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Drugs in Development / Clinical Trials—Updated March 17, 2015
Wednesday, April 1, 2015
Health Minister Dustin Duncan says the new drugs, Harvoni and Sovaldi, are better tolerated by patients than other therapies.
The drugs are said to cure 90 to 98 per cent of patients in as little as eight to 12 weeks.
When it comes to health care occupational risks, slips, trips, and falls are often the first to come to mind. Sharps also make the top of the list, but what is often overlooked is the cousin to sharps: splashes. Also known as mucocutaneous blood exposures, splashes are a notable risk for health care workers. Splashes—from routine activities such as cutting catheter bags, cleaning bedpans, and emptying suction cups—can land on a caregiver, where it can transfer a pathogen through the eyes, nose, or mouth.
Every year, the Centers for Disease Control and Prevention estimates that nearly 385,000 health care works in hospitals suffer sharps-related injuries. 1 By comparison, a study led by Doebbeling, et al. at the Veterans Administration found that in the previous three months, roughly 38 percent of all RNs had experienced a splash. Making the risk even more serious, they found that more than a quarter of these splashes went unreported. 2
Splashes, like sharps, can present serious risks to health care employees. This is because they can cause occupational-related infections, ranging from human immunodeficiency virus (HIV) to hepatitis B virus (HBV) to hepatitis C virus (HCV).3. Occupational exposures such as splashes can lead to lost work days, financial burden, and physical impairment. They also can take an emotional toll on those exposed.
*PPE = Personal protective equipment
Signature of House/Senate letter in support of the president’s proposed FY2016 budget to increase funding of the CDC’s Division of Viral Hepatitis to $62.8 million, and include the request in the member appropriations submissions
Support the repeal of the federal funding ban on syringe services programs
That their elected official would join the Congressional Hepatitis Caucus
Tuesday, March 31, 2015
The government has shifted all the burden of this scam to the shoulders of former PPP led government. PU medical experts had developed 100000 injections for cure of Hepatitis-C at the cost of Rs 7 million, but these have gone time barred while lying in stores, due to non-granting of permission by ministry of health and regulation for conducting laboratory test.
PU Molecular Biology department worked out plan to develop cheap Interferon injection for treatment of Hepatitis C and funds were also provided to the experts of the respective department. The said injection was developed within the span of 5 years time. The permission was sought from federal ministry for health and regulation for laboratory test of these injections. This application was kept unattended in Islamabad secretariat, for two years. These 100000 injections which were prepared for poor patients were wasted, for want of permission by the then minister of health Ejaz Jakhrani and secretary health Khushnood Lashari.
But some readers wrote to The Oregonian with questions. They wanted to know the cause of death. They asked why Smith, still bubbling with energy and ideas, died so relatively young.
On Monday, Smith's widow, Kim DeMent -- a remarkable woman in her own right, who runs Steven Smith Teamaker, dances with BodyVox and writes lyrically -- explained why. The answer should concern baby boomers and others, because it involves a little-known epidemic that could take many more lives at any age without simple precautions.
Smith died from complications of liver cancer.
Cooper, director of The Ottawa Hospital and Regional Hepatitis Program, sees thousands of hepatitis C patients, many of whom will benefit from the new drug therapy now that it is covered by the province.
“This is going to mean the difference between health or illness and death,” for many patients, he said.
The treatment, which costs around €45,000 to €55,000 per patient was given to the patients after doctors warned they were not responding to other drugs.
Dr Suzanne Norris, a gastroenterologist at St James's Hospital in Dublin, said the patients will continue to be monitored over the coming months to determine their response.
Earlier this year Health Minister Leo Varadkar said a programme was being put in place to provide early access to the powerful new direct-acting anti-viral drugs for Hepatitis C patients with the greatest clinical need, due to the advanced nature of their condition.